TECVAYLI (teclistama) Patient Assistance Program
Don’t let the high cost of brand specialty multiple myeloma BCMA bispecific therapy stand between you and the treatment you need. We help eligible patients access Tecvayli (teclistamab) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Tecvayli (teclistamab) is FDA-approved for the treatment of relapsed or refractory multiple myeloma in adults who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. It is given as a subcutaneous injection.
- Without assistance, the retail cost commonly runs $30,000–$45,000 per month at standard maintenance dosing, with annual treatment costs commonly reaching $400,000+.
- Through AffordMyPrescriptions, qualifying patients can access Tecvayli for a flat $69.95 per month — our advocacy team manages the entire enrollment, injections, and renewal process.
- There is no biosimilar version of Tecvayli available in the U.S. as of 2026. Tecvayli is dispensed through limited specialty pharmacy distribution, and treatment requires REMS-program enrollment due to cytokine release syndrome and neurotoxicity risks.
What Is Tecvayli Prescription Assistance Program?
The Tecvayli Prescription Assistance Program is a manufacturer-sponsored initiative that provides Tecvayli at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for relapsed/refractory multiple myeloma patients who are uninsured or underinsured, as well as Medicare beneficiaries.
Navigating the program on your own means dealing with eligibility verification, oncology-team coordination, prior-treatment documentation, REMS-program enrollment, hospital-based step-up dosing coordination, specialty pharmacy logistics, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing injection-schedule coordination and annual re-certification — so you focus on your treatment, not paperwork.
Pharmacy Price Comparison
- Without assistance, Tecvayli costs roughly $30,000–$45,000 per month. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Step-up doses (Days 1, 4, 7) | ~$10,000+ | Save thousand |
| Full weekly dose | ~$10,000.00 | Save ~$9,930/dose |
| Weekly dosing (monthly total) | ~$40,000+ | Save ~$39,930/mo |
| Every-2-week dosing | ~$20,000+/mo | Save ~$19,930/mo |
| Annual cost (typical) | ~$400,000+ | Save ~$399,000+/yr |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Tecvayli Prescription Program?
The Patient Assistance Program is free to apply for and provides Tecvayli at no medication cost if approved. But the process involves detailed applications, oncology-team coordination, prior-treatment documentation, REMS-program enrollment, hospital-based step-up dosing coordination (to monitor for cytokine release syndrome), and ongoing renewal management. Our $69.95/month service covers full advocacy.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Tecvayli:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
Still $30,000–$45,000 per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
- We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Tecvayli assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Tecvayli Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Tecvayli:
Tecvayli (teclistamab) is a first-in-class BCMA-directed bispecific T-cell engager used to treat relapsed or refractory multiple myeloma in heavily pre-treated patients. It targets B-cell maturation antigen (BCMA) on myeloma cells and CD3 on T cells. Treatment begins with hospital-based step-up dosing followed by weekly or every-2-week subcutaneous maintenance
How Tecvayli Works:
Tecvayli is a bispecific antibody that targets BCMA, a protein highly expressed on multiple myeloma cells. It works by simultaneously binding to BCMA on cancer cells and CD3 on T cells, physically forcing the patient’s own immune system to recognize and destroy the tumor. As the first BCMA-directed bispecific approved for myeloma, it provides a powerful treatment option for patients who have already progressed on several prior therapies.
Form and use:
This medication is administered via subcutaneous injection, starting with a three-step induction phase in a hospital to monitor for side effects. Following this “step-up” process, patients transition to a weekly maintenance dose of 1.5 mg/kg. Those who achieve a stable remission may eventually be eligible to move to a less frequent, every-two-week dosing schedule.
Generic availability:
As of 2026, there is no biosimilar version of Talvey available in the United States. While it remains a unique branded therapy, other advanced options for late-stage multiple myeloma exist, such as the bispecific antibodies Tecvayli and Elrexfio, or CAR-T cell therapies like Carvykti. The choice between these specialized treatments depends on the patient’s prior therapy history and clinical needs.
Warnings:
Tecvayli carries boxed warnings for cytokine release syndrome (CRS), neurological toxicity, and serious infections, which is why initial dosing occurs in a clinical setting. Other significant risks include liver toxicity, low immune globulin levels, and potential embryo-fetal harm. Patients must be educated to immediately identify and report signs of CRS or neurological changes to their oncology team.
FAQ (Frequently Asked Questions)
How Much Does Tecvayli Cost Without Insurance?
The retail cost commonly runs $30,000–$45,000 per month, with annual costs reaching $400,000+. Through AffordMyPrescriptions, qualifying patients receive Tecvayli at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
How Is Tecvayli Different From CAR-T Or Other Myeloma Therapies?
Tecvayli is an off-the-shelf bispecific antibody that targets BCMA on myeloma cells and CD3 on T cells. CAR-T cell therapies (Carvykti, Abecma) also target BCMA but require leukapheresis and engineering of the patient’s own T cells — a much longer process. Tecvayli is generally easier to access and start than CAR-T, but CAR-T may produce deeper or more durable responses in some patients. Whether one is a better fit depends on disease state, prior treatments, performance status, and access to a CAR-T center.
Why Are The First Doses Given In A Hospital?
Tecvayli can cause cytokine release syndrome (CRS) — an immune reaction with fever, low blood pressure, hypoxia, and other signs — most commonly during the step-up dosing phase. The step-up schedule (smaller doses first on Days 1, 4, 7) and hospital monitoring during these early doses help detect and manage CRS early. After successful step-up, ongoing dosing can be given in outpatient settings.
Are There Other Bispecifics For Multiple Myeloma I Should Know About?
Yes. Other myeloma bispecifics include elranatamab (Elrexfio, BCMA-targeted) and talquetamab (Talvey, GPRC5D-targeted). For patients who progress on BCMA-directed therapies, switching to a non-BCMA bispecific like Talvey can be effective. CAR-T therapies are also options. Whether one is a better fit depends on prior treatments and clinical situation.
Can I Get Tecvayli Through The PAP If I Have Medicare?
Yes. Medicare Part D beneficiaries can typically qualify for Tecvayli Patient Assistance, especially if you face specialty-tier copays you cannot afford. The manufacturer’s commercial copay savings program is reserved for commercially insured patients only — but the underlying PAP supports Medicare patients who meet income criteria.
What If My Application Is Denied?
If your initial application is denied, we explore alternatives — the manufacturer’s copay savings program if you have commercial insurance, independent foundations such as the International Myeloma Foundation, Multiple Myeloma Research Foundation, Leukemia & Lymphoma Society, PAN Foundation, or HealthWell Foundation, or asking your oncology team whether a different bispecific or CAR-T approach would be appropriate. If we cannot find a path, you will not be charged our service fee.
Take Control of Your Medication Costs
If you are struggling with the high cost of Tecvayli, our team may be able to help you access assistance programs designed to make brand specialty BCMA bispecific myeloma therapy affordable. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.